Lates News

Economic Information Daily reported that on May 21st, Huajin Securities issued a research report giving a buy rating on Lianlong (300596.SZ). The reasons for the rating mainly include: 1) the market share and gross profit margin of the high molecular anti-aging business have both increased year-on-year; 2) the operating rate of lubricant additives has increased, and the initial results of developing major customers have been seen; 3) the technology of life science products is gradually maturing, transitioning from research and development to dual-track operation of research and development and marketing; 4) the future prospects of emerging businesses are promising.